Clinical Trials Browser

Active not recruiting × Interventional × Adenocarcinoma × Clear all

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT06564844 2026-05-22

TROPION-Lung12

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04627246 2026-05-08

Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms

NCT04644770 2026-05-08

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT03132922 2026-05-07

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Phase 1 Active not recruiting

71 enrolled 20 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03504397 2026-05-04

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05063565 2026-04-29

ROWAN

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT03653507 2026-04-17

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT01512589 2026-04-15

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT02864992 2026-04-13

VISION

Phase 2 Active not recruiting

337 enrolled 13 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06939452 2026-04-07

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Phase 2 Active not recruiting

Adenocarcinoma

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2 Active not recruiting

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms

NCT07302451 2026-01-06

REDI-CaP

Phase 2 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT00756639 2025-12-17

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Phase 2 Active not recruiting

CNSGenitourinary

Adenocarcinoma, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01088789 2025-08-26

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Phase 2 Active not recruiting

71 enrolled 13 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT05226507 2025-08-08

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Carcinoma, Neoplasms, Ovarian Neoplasms

NCT01952223 2025-07-30

PEACE2

Phase 3 Active not recruiting

Adenocarcinoma, Recurrence

NCT05604560 2025-07-23

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT04879368 2025-07-17

INTEGRATEIIb

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT05128487 2024-11-25

A Study of NDI 1150-101 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

GenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01171300 2024-07-10

Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients

Phase NA Active not recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT02509286 2024-05-08

ESOPEC

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT03488667 2023-05-19

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms